查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842001

全球细胞和基因治疗CDMO市场：市场规模、份额和趋势分析（按阶段、产品、适应症和地区划分），细分市场预测（2025-2033年）

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

细胞与基因治疗CDMO市场摘要

全球细胞和基因治疗 CDMO 市场预计到 2024 年将达到 43.1 亿美元，到 2033 年将达到 271.2 亿美元，2025 年至 2033 年的复合年增长率为 23.03%。

该行业的发展动力来自不断扩大的细胞和基因治疗产品组合、对罕见疾病日益增长的研究兴趣，以及公共和私营部门对研发的大量投资。

其他推动成长的因素包括对细胞和基因治疗外包服务日益增长的需求、癌症等慢性疾病的日益普遍、併购活动的激增以及细胞和基因治疗开发过程中持续不断的技术创新。市场成长的主要驱动力是生物技术和製药业不断增加的研发资金和对细胞和基因治疗（CGT）疗法的投资。细胞和基因疗法在治疗包括癌症、遗传性疾病和某些感染疾病在内的多种疾病方面具有巨大潜力。因此，这些治疗方法的巨大潜力激发了公共和私营部门对创新细胞和基因治疗方法开发和发现的浓厚兴趣。目前，大多数大型製药公司都在投资CGT以建立强大的市场地位。创业投资，尤其是在生命科学领域的投资，已显着增加。

此外，不断增长的临床研发管线以及对生产所需专业知识和基础设施外包的持续依赖也是推动市场成长的因素。根据clinicaltrials.org网站发布的数据，目前有超过2000项正在进行的细胞和基因治疗临床试验处于不同的研发阶段，每项从早期到晚期的进展都会增加对病毒载体、质体和临床级细胞处理的需求。 FDA在2023-2024年核准了Casgevy（用于治疗镰状细胞贫血症）和Elevidys（用于治疗Duchenne氏肌肉失养症）等新型疗法，EMA也核准了Roctavian（用于治疗A型血友病） ，这些都凸显了先进疗法进入商业化阶段的强劲势头。大多数从事这些创新的中小型生物技术公司缺乏大规模的GMP设施，因此与CDMO（合约研发生产机构）合作对于惠及患者至关重要。为了因应这一成长，包括 Lonza、Catalent、无锡先进疗法和赛默飞世尔科技在内的领先企业正大力投资扩大其病毒载体和细胞疗法的生产能力，这表明它们对持续的外包需求充满信心。随着核准速度加快、研发管线不断扩展以及生产需求超过企业内部产能，这些因素共同推动市场持续高速成长。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：细胞与基因治疗CDMO市场：驱动因素、趋势与范围

  • 市场体系展望
  • 细胞与基因治疗CDMO市场动态
  • 技术格局
  • 定价模式分析
  • 细胞与基因治疗CDMO市场：分析工具

第四章：细胞和基因治疗CDMO市场：按阶段分類的估算和趋势分析

  • 细分仪表板
  • 全球细胞与基因治疗CDMO市场：趋势分析及发展阶段
  • 全球细胞基因治疗CDMO市场规模及发展趋势分析（依阶段划分，2021-2033年）
  • 临床前
  • 临床

第五章：细胞和基因治疗CDMO市场：按产品分類的估算和趋势分析

  • 细分仪表板
  • 全球细胞和基因治疗CDMO市场：波动分析（按产品分类）
  • 全球细胞基因治疗CDMO市场规模及产品趋势分析（2021-2033年）
  • 基因治疗
    • 体外
    • 体内
  • 基因改造细胞疗法
    • CAR-T细胞疗法
    • CAR-NK细胞疗法
    • TCR-T细胞疗法
    • 其他的
  • 细胞疗法

第六章：细胞与基因治疗CDMO市场：依适应症分類的估算与趋势分析

  • 细分仪表板
  • 全球细胞和基因治疗CDMO市场：按适应症分類的波动分析
  • 全球细胞及基因治疗CDMO市场规模及趋势分析（依适应症划分）（2021-2033年）
  • 瘤
  • 感染疾病
  • 神经系统疾病
  • 罕见疾病
  • 其他的

7. 细胞和基因治疗CDMO市场：区域估算和趋势分析（按服务、型号和最终用途划分）

  • 市场概览：按地区
  • 全球市场概览：按地区划分
  • 市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 阿曼
    • 卡达

第八章 竞争情势

  • 公司分类
  • 细胞和基因治疗CDMO市场份额分析（2024年）
  • 公司简介
    • Lonza
    • Catalent, Inc
    • Cytiva
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • WuXi AppTec
    • AGC Biologics
    • OmniaBio
    • Charles River Laboratories
    • Rentschler Biopharma SE
Product Code: GVR-4-68040-167-4

Cell And Gene Therapy CDMO Market Summary

The global cell and gene therapy CDMO market size was valued at USD 4.31 billion in 2024 and is projected to reach USD 27.12 billion by 2033, growing at a CAGR of 23.03% from 2025 to 2033. The industry is driven by the expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, and substantial investments from both public and private sectors in research and development.

The rising demand for outsourced services related to cell and gene therapies, the increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process are also fueling the growth. The market is primarily driven by the increased R&D funding and investments in cell and gene therapeutics (CGT) by the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production are also factors which is driving market growth. According to the data published by clinicaltrials.org there are currently over 2,000 ongoing clinical trials in cell and gene therapies that are progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA's approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage. Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

Global Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell and gene therapy CDMO market report based on phase, product, indication, and region.

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-clinical
  • Clinical
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Gene Therapy
    • Ex-vivo
    • In-vivo
  • Gene-Modified Cell Therapy
    • CAR T-cell therapies
    • CAR-NK cell therapy
    • TCR-T cell therapy
    • Others
  • Cell Therapy
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Cell And Gene Therapy CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Cell And Gene Therapy CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Cell And Gene Therapy CDMO Market Phase Movement Analysis
  • 4.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
  • 4.4. Pre-clinical
    • 4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Clinical
    • 4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Cell And Gene Therapy CDMO Market Product Type Movement Analysis
  • 5.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
  • 5.4. Gene Therapy
    • 5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Ex-vivo
      • 5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. In-vivo
      • 5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Gene-Modified Cell Therapy
    • 5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. CAR T-cell therapies
      • 5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. CAR-NK cell therapy
      • 5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. TCR-T cell therapy
      • 5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Other
      • 5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cell Therapy
    • 5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Cell And Gene Therapy CDMO Market Indication Movement Analysis
  • 6.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Infectious Diseases
    • 6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Neurological disorders
    • 6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Rare Diseases
    • 6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.6. Oman
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.7. Qatar
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Cell And Gene Therapy CDMO Market Share Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Catalent, Inc
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Cytiva
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Thermo Fisher Scientific Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. WuXi AppTec
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AGC Biologics
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. OmniaBio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Charles River Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Rentschler Biopharma SE
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 4 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 5 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 7 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 9 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 10 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 11 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 12 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 13 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 15 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 17 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 18 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 20 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 21 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 22 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 23 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 24 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25 France Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 26 France Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 27 France Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 28 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 29 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 30 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 31 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 32 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 33 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 34 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 35 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 36 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 37 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 38 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 39 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 40 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 41 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 42 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 47 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 48 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 49 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 50 China Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 51 China Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 52 China Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 53 India Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 54 India Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 55 India Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 56 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 57 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 58 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 59 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 60 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 61 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 62 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 63 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 65 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 67 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 68 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 69 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 70 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 71 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 72 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 73 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 74 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 75 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 77 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 78 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 79 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 80 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 81 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 85 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 86 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 87 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 88 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 89 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 90 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 91 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 92 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 93 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 94 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 95 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 96 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cell And Gene Therapy CDMO Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 Cell And Gene Therapy CDMO Market dynamics
  • Fig. 19 Total R&D drug pipeline size, 2021 - 2024
  • Fig. 20 Total drug pipeline by development phase, 2024
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 PESTEL analysis
  • Fig. 23 Cell And Gene Therapy CDMO Market Phase outlook: Segment dashboard
  • Fig. 24 Cell And Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
  • Fig. 25 Pre-clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Cell And Gene Therapy CDMO Market Product Type outlook: Segment dashboard
  • Fig. 28 Cell And Gene Therapy CDMO Market, by Product Type segment: Market share, 2025 & 2033
  • Fig. 29 Gene Therapy Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Ex-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 In-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 CAR T-cell therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 CAR-NK cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 TCR-T cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Cell And Gene Therapy CDMO Market Indication outlook: Segment dashboard
  • Fig. 39 Cell And Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
  • Fig. 40 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Infectious Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Neurological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Rare Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Regional market: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 France Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 China Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 India Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 102 Market participant categorization
  • Fig. 103 Heat map analysis